Q-omics provides the consensus-scored HMCN1 profile across patient tissues and cancer cell-line models. HMCN1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HMCN1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HMCN1 protein abundance shows 21,526 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, and BRCA as cancer lineages where HMCN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMCN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMCN1 survival associations across molecular data types. HMCN1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (14) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMCN1 RNA expression–survival associations across cancer types. High HMCN1 expression shows unfavorable associations in KIRP, BLCA, MESO and STAD, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HMCN1 RNA expression.
This table summarizes HMCN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HMCN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMCN1 shows lower tumor expression in KICH, LUSC, LUAD and KIRP and higher tumor expression in KIRC and UCEC. The KIRC box plot shows higher HMCN1 RNA expression in tumor versus normal tissue (log2 FC = +1.329, t-test p < 0.001).
This table shows molecular features associated with HMCN1 in patient tissues and cancer cell lines. In patient samples, HMCN1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, HMCN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
